$PPCBJul 7, 2026, 8:30 AM ETAI processed
PPCB inks MOU with Avance to run Phase 1b First‐in‐Human trial of PRP
AI Summary
Propanc Biopharma (PPCB) signed a Memorandum of Understanding with Avance Clinical to support the clinical delivery of a First‐in‐Human Phase 1b trial of its lead candidate PRP in advanced solid tumors; the planned study will evaluate safety, tolerability, pharmacokinetics, immunogenicity and preliminary clinical activity. Avance positions itself as an experienced early‐phase oncology CRO that will leverage Australian advantages (faster ethics approval and an R&D tax rebate) to accelerate the program, but the announcement is an MOU of intent rather than a finalized services contract and provides no timelines, patient counts, or costs.
Positives
- Signed MOU to support Phase 1b First‑in‑Human trial of PRP in advanced solid tumors
- Partner (Avance) has documented early‑phase oncology CRO experience and adaptive dose‑finding expertise
- Plan targets standard Phase 1 endpoints (safety, tolerability, PK, immunogenicity) enabling progression toward proof‑of‑concept
Negatives
- Announcement is a non‑binding MOU, not a completed CRO services agreement
- No timeline, patient enrollment size, or budget/cost details disclosed
- Program remains early stage (Phase 1b) with inherent clinical and regulatory risk